Thaddeus Beeker, MD
Hematology & Oncology · Mobile, ALNPI 1780637579
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 432 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in AL, where the typical reported total is $7,159.
Across 432 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Pfizer$699
- Bristol Myers Squibb$675
- Merck$623
- AstraZeneca$536
- Genentech USA, Inc.$470
- plus $4K from 47 others
Across 14 payments — averaging $13,503 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$138K
- Eli Lilly$49K
- Pfizer$2K
What the payments were for
- Food & beverage$7,90795%
- Education$4305%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,337 in reported general payments places this provider in the 50th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 103 | $1,962,262 |
| CalquenceAcalabrutinib Maleate | 51 | $742,364 |
| Lenalidomide | 37 | $532,053 |
| VerzenioAbemaciclib | 33 | $491,311 |
| CabometyxCabozantinib S-Malate | 12 | $288,597 |
| TasignaNilotinib Hcl | 12 | $240,757 |
| KisqaliRibociclib Succinate | 15 | $239,842 |
| ImbruvicaIbrutinib | 14 | $213,786 |
| BrukinsaZanubrutinib | 11 | $172,360 |
| XtandiEnzalutamide | 11 | $145,243 |
| GleevecImatinib Mesylate | 13 | $128,925 |
| VenclextaVenetoclax | 25 | $79,951 |
| AranespDarbepoetin Alfa In Polysorbat | 12 | $36,553 |
| EliquisApixaban | 39 | $29,296 |
| NeupogenFilgrastim | 12 | $29,065 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $675 | $1,962,262103 claims |
| AstraZenecaCalquence | $536 | $742,36451 claims |
| NovartisTasigna, Kisqali, Gleevec | $1,062 | $609,52440 claims |
| Lilly USA, LLCVerzenio | $185 | $491,31133 claims |
| Exelixis Inc.Cabometyx | $106 | $288,59712 claims |
| Beigene USA, Inc.Brukinsa | $67 | $172,36011 claims |
| Astellas Pharma US IncXtandi | $240 | $145,24311 claims |
| AbbVieVenclexta | $36 | $79,95125 claims |
| AmgenAranesp, Neupogen | $328 | $65,61924 claims |
| PfizerEliquis | $699 | $29,29639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Mobile
- Anita MazloomMobile$20K
- Sherri ArledgeMobile$19K
- Daniel CameronMobile$17K
- Jose Galeas SorianoMobile$17K
- Michael MeshadMobile$14K
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.